- Home
- MBIO vs BDRX Comparison
MBIO vs BDRX Comparison
Compare MBIO & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBIO | BDRX |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MBIO | BDRX |
|---|---|---|
| Price | $1.09 | $5.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 102.8K | ★ 2.4M |
| Earning Date | 11-07-2025 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.89 | $3.58 |
| 52 Week High | $21.95 | $92.00 |
Technical Indicators
Market Signals| Indicator | MBIO | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.70 | 50.55 |
| Support Level | $1.06 | $4.55 |
| Resistance Level | $1.31 | $7.22 |
| Average True Range (ATR) | 0.09 | 1.47 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 8.11 | 31.98 |
Price Performance
Historical ComparisonAbout MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.